Toll-like receptor alterations in myelodysplastic syndrome

Leukemia

Volumn 27, Issue 9, 2013, Pages 1832-1840

  Wei, Y ^a   Dimicoli, S ^a   Bueso Ramos, C ^a   Chen, R ^b   Yang, H ^a   Neuberg, D ^c   Pierce, S ^a   Jia, Y ^a   Zheng, H ^a   Wang, H ^b   Wang, X ^b   Nguyen, M ^a   Wang, S A ^a   Ebert, B ^d   Bejar, R ^d   Levine, R ^e   Abdel Wahab, O ^e   Kleppe, M ^e   Ganan Gomez, I ^a,f   Kantarjian, H ^a   Garcia Manero, G ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

IL 8; innate immunity; JMJD3; myelodysplastic syndromes; Toll like receptor

Indexed keywords

HISTONE DEMETHYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; SHORT HAIRPIN RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENETIC VARIABILITY; HISTONE METHYLATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INNATE IMMUNITY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGENS, CD34; BASE SEQUENCE; BONE MARROW CELLS; CELL DIFFERENTIATION; ERYTHROID CELLS; GENE EXPRESSION; GENE ORDER; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-8; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTATION; MYELODYSPLASTIC SYNDROMES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6; TOLL-LIKE RECEPTORS;

EID: 84883742414     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.180     Document Type: Article

References (29)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-1885.
2. Wei Y, Chen R, Dimicoli S, Bueso-Ramos C, Neuberg D, Pierce S et al. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34\+ cells. Leukemia 2013; e-pub ahead of print 29 March 2013; doi:10.1038/leu.2013.91.
3. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801. (Pubitemid 43261452)
4. De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycombmediated gene silencing. Cell 2007; 130: 1083-1094. (Pubitemid 47410272)
5. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
6. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
7. Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009; 31: 873-884.
8. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169: 10-14. (Pubitemid 34686113)
9. Merx S, Neumaier M, Wagner H, Kirschning CJ, Ahmad-Nejad P. Characterization and investigation of single nucleotide polymorphisms and a novel TLR2 mutation in the human TLR2 gene. Hum Mol Genet 2007; 16: 1225-1232. (Pubitemid 47062718)
10. Janssens S, Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell 2003; 11: 293-302. (Pubitemid 36293825)
11. Conze DB, Wu CJ, Thomas JA, Landstrom A, Ashwell JD. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor-and toll-like receptor-mediated NF-kappaB activation. Mol Cell Biol 2008; 28: 3538-3547. (Pubitemid 351657114)
12. Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010; 116: 4251-4261.
13. Sioud M, Floisand Y. TLR agonists induce the differentiation of human bone marrow CD34\+ progenitors into CD11c\+ CD80/86\+ DC capable of inducing a Th1-type response. Eur J Immunol 2007; 37: 2834-2846. (Pubitemid 47578303)
14. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A et al. Identification of miR-145 and miR-146a as mediators of the 5qsyndrome phenotype. Nat Med 2010; 16: 49-58.
15. Rhyasen GW, Starczynowski DT. Deregulation of microRNAs in myelodysplastic syndrome. Leukemia 2012; 26: 13-22.
16. Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, Akira S et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006; 24: 801-812. (Pubitemid 43867369)
17. Esplin BL, Shimazu T, Welner RS, Garrett KP, Nie L, Zhang Q et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol 2011; 186: 5367-5375.
18. De Luca K, Frances-Duvert V, Asensio MJ, Ihsani R, Debien E, Taillardet M et al. The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate. Leukemia 2009; 23: 2063-2074.
19. Kawai T, Akira S. TLR signaling. Cell death Differ 2006; 13: 816-825.
20. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annual Rev Immunol 2011; 29: 139-162.
21. Vinh DC, Patel SY, Uzel G, Anderson VL, Freeman AF, Olivier KN et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010; 115: 1519-1529.
22. Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012; 22: 466-478.
23. Maratheftis CI, Andreakos E, Moutsopoulos HM, Voulgarelis M. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res 2007; 13: 1154-1160. (Pubitemid 46424055)
24. Fujii S, Shimizu K, Klimek V, Geller MD, Nimer SD, Dhodapkar MV. Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol 2003; 122: 617-622. (Pubitemid 36995216)
25. Chan AC, Neeson P, Leeansyah E, Tainton K, Quach H, Prince HM et al. Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia 2010; 24: 592-600.
26. Baldridge MT, King KY, Goodell MA. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol 2011; 32: 57-65.
27. Anur P, Yates J, Garbati MR, Vanderwerf S, Keeble W, Rathbun K et al. p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC-and FANCAdeficient mononuclear phagocytes. Blood 2012; 119: 1992-2002.
28. Vanderwerf SM, Svahn J, Olson S, Rathbun RK, Harrington C, Yates J et al. TLR8-dependent TNF-(alpha) overexpression in Fanconi anemia group C cells. Blood 2009; 114: 5290-5298.
29. de Almeida LA, Macedo GC, Marinho FA, Gomes MT, Corsetti PP, Silva AM et al. Toll-like receptor 6 plays an important role in host innate resistance to Brucella abortus infection in mice. Infect Immun 2013; 81: 1654-1662.